|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.45 - 2.54|
|52 Week Range||2.28 - 10.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, June 28, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that the company will be attending as a sponsor. at the 28 th Annual International ...
NEW YORK, June 19, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that the United States Patent and Trademark Office has issued a Notice of ...
AXIM® Biotechnologies, Inc. (AXIM) (AXIM), a world leader in cannabinoid research and development, today announced that it has reached a long-term purchase agreement for pharmaceutical-grade dronabinol with Noramco, a global leader in the production of controlled substances for the pharmaceutical industry. The agreement outlines an initial purchase of the Active Pharmaceutical Ingredient (API) dronabinol, which is a synthetic form of tetrahydrocannabinol (THC), to be used in AXIM’s clinical trials for treatment of chemotherapy-induced nausea/vomiting (CINV) and anorexia associated with weight loss in patients with cancer or AIDS.
NEW YORK, April 23, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that the company has secured additional funding needed to further its clinical ...
OTC:AXIM Summary • AXIM Biotechnologies (OTC:AXIM) holds the intellectual property rights to the controlled-release, trans-mucosal (chewing gum) drug delivery platform for medical cannabinoids. o The company ...
SAN DIEGO , Feb. 28, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , announced that its major investment company AXIM® ...
As marijuana legalization begins to slowly roll out state by state, it follows that marijuana-based businesses have cropped up, and many are trying their hand in the public markets. Regrettably, CANN is losing more and more money on marijuana services every year and is also burning cash.
• During the fourth quarter of 2017, cannabis stocks climbed sharply (North American Marijuana Index +137%) reflecting increased investor interest and positive fundamental tailwinds. • AXIM Biotechnologies is well positioned to benefit from the overall medical cannabinoid investment theme and is expected to achieve significant milestones during 2018. Making its debut on the Toronto Stock Exchange in April 2017, the Horizons Medical Marijuana Life Sciences ETF (HMMJ.TO) sought to mimic the North American Medical Marijuana Index, a basket of publicly-listed North American companies with significant business activities in the marijuana industry.
Alternate Health Begins Beta Testing of FlorPass Patient Management Software System in Key Market
SAN ANTONIO , Dec. 11, 2017 /PRNewswire/ -- Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international, vertically-integrated medical cannabis ...
Alternate Health's Investor Webcast And Presentation Now Available For On-Demand Viewing At VirtualInvestorConferences.com